Paper · 35534455
Targeting double-strand break indel byproducts with secondary guide RNAs improves Cas9 HDR-mediated genome editing efficiencies.
Bodai Z and 3 others. Nat Commun, 2022. Cited by 27 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Targeting double-strand break indel byproducts with secondary guide RNAs improves Cas9 HDR-mediated genome editing efficiencies. Papers, record 35534455. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35534455
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Gene Editing | Major topic |
| Animals | |
| CRISPR-Cas Systems | |
| DNA End-Joining Repair | |
| Mammals | |
| Recombinational DNA Repair | |
| RNA, Guide, CRISPR-Cas Systems |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| DP5 OD023098 | NIH HHS | United States | DP5OD023098 | PubMed and NIH | NIH RePORTER |
| R01 AI162911 | NIAID NIH HHS | United States | R01AI162911 | PubMed and NIH | NIH RePORTER |
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References54
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27,120,160 | Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. | Nature | 2016 | https://conductscience.org/library/papers/27120160 | PubMed |
| 2 | 26,735,016 | High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. | Nature | 2016 | https://conductscience.org/library/papers/26735016 | PubMed |
| 3 | 28,985,763 | Crossing enhanced and high fidelity SpCas9 nucleases to optimize specificity and cleavage. | Genome Biol | 2017 | https://conductscience.org/library/papers/28985763 | PubMed |
| 4 | 30,271,937 | Increasing Cas9-mediated homology-directed repair efficiency through covalent tethering of DNA repair template. | Commun Biol | 2018 | https://conductscience.org/library/papers/30271937 | PubMed |
| 5 | 25,184,501 | Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. | Nat Biotechnol | 2014 | https://conductscience.org/library/papers/25184501 | PubMed |
| 6 | 31,634,902 | Search-and-replace genome editing without double-strand breaks or donor DNA. | Nature | 2019 | https://conductscience.org/library/papers/31634902 | PubMed |
| 7 | 26,789,497 | Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. | Nat Biotechnol | 2016 | https://conductscience.org/library/papers/26789497 | PubMed |
| 8 | 23,907,390 | Optimization of scarless human stem cell genome editing. | Nucleic Acids Res | 2013 | https://conductscience.org/library/papers/23907390 | PubMed |
| 9 | 28,931,002 | Enhanced proofreading governs CRISPR-Cas9 targeting accuracy. | Nature | 2017 | https://conductscience.org/library/papers/28931002 | PubMed |
| 10 | 25,798,939 | Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. | Nat Biotechnol | 2015 | https://conductscience.org/library/papers/25798939 | PubMed |
1 to 10 of 54
See all 54 referencesCited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,486,986 | Efficient and precise programmable DNA knock-in without double-strand breaks. | Nature | 2026 | https://conductscience.org/library/papers/42486986 | PubMed |
| 42,353,300 | CRISPR Gene Tagging for Illuminating Endogenous Protein Dynamics. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42353300 | PubMed |
| 42,306,789 | Fundamentals and emerging frontiers in p53-targeted drug development. | Biochem Biophys Rep | 2026 | https://conductscience.org/library/papers/42306789 | PubMed |
| 42,261,595 | Harnessing Deep Learning Models for Guide RNA Optimization and Off-Target Prediction in CRISPR Systems. | Biotechnol J | 2026 | https://conductscience.org/library/papers/42261595 | PubMed |
| 41,445,195 | Transient muscle expression of mitoARCUS in mice leads to sustained reductions in pathogenic mtDNA and reduces fatigability. | Mol Ther | 2026 | https://conductscience.org/library/papers/41445195 | PubMed |
| 41,365,890 | Efficient high-precision transgene knock-in by Recombinases (Redα/β)-enhanced DNA integration-CRISPR-Cas9 (RED-CRISPR). | Nat Commun | 2025 | https://conductscience.org/library/papers/41365890 | PubMed |
| 41,361,167 | Search-and-remove genome editing allows selection of cells by DNA sequence. | Nat Commun | 2025 | https://conductscience.org/library/papers/41361167 | PubMed |
| 40,156,857 | Precision genome editing and in-cell measurements of oxidative DNA damage repair enable functional and mechanistic characterization of cancer-associated MUTYH variants. | Nucleic Acids Res | 2025 | https://conductscience.org/library/papers/40156857 | PubMed |
| 38,877,530 | CRISPR/Cas9 gene editing: a novel strategy for fighting drug resistance in respiratory disorders. | Cell Commun Signal | 2024 | https://conductscience.org/library/papers/38877530 | PubMed |
| 38,255,224 | Increasing Gene Editing Efficiency via CRISPR/Cas9- or Cas12a-Mediated Knock-In in Primary Human T Cells. | Biomedicines | 2024 | https://conductscience.org/library/papers/38255224 | PubMed |
1 to 10 of 18
See all 18 cited byGenes20
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ACTB | 60 | PubTator's text mining | https://conductscience.org/library/genes/60 | NCBI Gene |
| APOB | 338 | PubTator's text mining | https://conductscience.org/library/genes/338 | NCBI Gene |
| EPHA8 | 2,046 | PubTator's text mining | https://conductscience.org/library/genes/2046 | NCBI Gene |
| EPHB3 | 2,049 | PubTator's text mining | https://conductscience.org/library/genes/2049 | NCBI Gene |
| FANCF | 2,188 | PubTator's text mining | https://conductscience.org/library/genes/2188 | NCBI Gene |
| HBB | 3,043 | PubTator's text mining | https://conductscience.org/library/genes/3043 | NCBI Gene |
| HEXA | 3,073 | PubTator's text mining | https://conductscience.org/library/genes/3073 | NCBI Gene |
| HIRA | 7,290 | PubTator's text mining | https://conductscience.org/library/genes/7290 | NCBI Gene |
| LIG4 | 3,981 | PubTator's text mining | https://conductscience.org/library/genes/3981 | NCBI Gene |
| LINC01509 | 101,928,720 | PubTator's text mining | https://conductscience.org/library/genes/101928720 | NCBI Gene |
1 to 10 of 20
See all 20 genesDrugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35534455
GET https://conductscience.org/api/papers/v1/35534455/references?page=2